Host: The Japanese Pharmacological Society
Name : The 96th Annual Meeting of the Japanese Pharmacological Society
Number : 96
Location : [in Japanese]
Date : November 30, 2022 - December 03, 2022
Cardiotoxicity is one of the most significant adverse effects of anti-cancer agents, and is responsible for considerable morbidity and mortality. In particular, the most frequent and serious effect is heart failure with ventricular dysfunction. Thus, contractility is a key cardiac safety issue in drug development.
Human stem cell technology holds great promise as in vitro models to assess novel drug candidates during drug development. If human iPS cell-derived cardiomyocytes (iPSC-CMs) can be used to further improve the predictability of safety in humans, it is expected to revolutionize the drug discovery process by improving drug development efficiency, reducing cost and ensuring the patients' safety.
We have developed imaging-based method for cardiac contractility, which can detect and quantitate the strain of iPSC-CMs during their contraction and relaxation. As expected, treatment with anti-cancer agents, such as doxorubicin, inhibited contraction as well as relaxation speed using iPSC-CMs. Based on our experience about proarrhythmia risk assessment using iPSC-CMs, we try to get confidence with in vitro contractility assessment.
In this symposium, we would like to show our cardiac toxicity approach to predict clinical cardiotoxicity risk, and discuss future perspectives of cardio-oncology field.
